Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

MADRID — Roche on Sat­ur­day tout­ed ad­di­tion­al da­ta from a study show­ing that its drug Ale­cen­sa of­fers “un­prece­dent­ed” dis­ease-free sur­vival in pa­tients with com­plete­ly re­sect­ed ALK-pos­i­tive non-small cell lung can­cer.

Last week, Roche un­veiled topline da­ta to its Phase III ALI­NA study, show­ing the drug de­liv­ered a 76% drop in dis­ease re­cur­rence or death when com­pared with plat­inum-based chemother­a­py in pa­tients who have had their stage IB to II­IA tu­mors re­sect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER